IMMUNOGLOBULIN A NEPHROPATHY
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to protect kidneys in autoimmune diseases
Disease control TerminatedThis study tested an investigational drug, ALXN2050, in adults with two serious kidney diseases: lupus nephritis and IgA nephropathy. The goal was to see if adding ALXN2050 to standard care could better reduce protein in the urine and protect long-term kidney function. The trial …
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Drug trial aims to protect kidneys in autoimmune diseases
Disease control TerminatedThis study tested whether the drug ravulizumab could help control kidney damage in adults with lupus nephritis or IgA nephropathy. About 123 participants were randomly assigned to receive either the drug or a placebo infusion to see if it safely reduced protein in their urine, a …
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC